The clinical efficacy of angiotensin II type1 receptor blockers on inflammatory markers in patients with hypertension: a multicenter randomized-controlled trial; MUSCAT-3 study-Reference-Cited by-同舟云学术

The clinical efficacy of angiotensin II type1 receptor blockers on inflammatory markers in patients with hypertension: a multicenter randomized-controlled trial; MUSCAT-3 study

Published:2018-11-29 Issue:3 Volume:24 Page:255-261
ISSN:1354-750X
Container-title:Biomarkers
language:en
Short-container-title:Biomarkers

Author:

Umebayashi Ryoko¹,Uchida Haruhito A.¹²,Okuyama Yuka¹,Kakio Yuki¹,Hanayama Yoshihisa¹³,Shikata Kenichi¹⁴,Wada Jun¹

Affiliation:

1. Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

2. Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

3. Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;

4. Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Clinical Biochemistry,Biochemistry

Link

https://www.tandfonline.com/doi/pdf/10.1080/1354750X.2018.1548033

Reference38 articles.

1. Normotensive Ischemic Acute Renal Failure

2. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes

3. The specific role of chemokines in atherosclerosis